Healthcare imaging solution company Median Technologies (ALMDT:PA) reported revenues of EUR20.5m as of 31 December 2021.
This marks an improvement of 52% when compared to revenues in 2020.
The company generated EUR5.1m in revenue in the Q4 2021, a rise of 24.4% over the revenue of EUR4.1m in the Q4 2020.
In addition, the company's order backlog was EUR58m as of 31 December 2021, up by EUR6.3m from 31 December 2020 and EUR3,8m from 30 September 2021, respectively. The increase confirms the growth momentum recovery that began in the third quarter after several quarters impacted by the health crisis.
As of 31 December 2021, the company's cash and cash equivalents were EUR39m, a growth over EUR16m as of 31 December 2020.
For 2021, the company was selected as preferred vendor for one of the world's Top 3 pharmaceutical companies to implement this client's imaging strategy in clinical trials on key oncology indications. The company was inspected by the FDA at its location of Sophia Antipolis, France and participated in 4 NMPA inspections (Chinese authority regulating drugs and medical devices) on behalf of a several clients.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886